GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.
Related Posts
The Scion of the Ziploc Empire Is on a Crusade to Rein In Plastic Waste
SC Johnson’s CEO confronts a “versatile” material that has propelled the family business and is also a “profound global pollutant.”
Squarespace Gets Sweetened $7.2 Billion Offer From Permira to Go Private
The new offer price is 5.7% higher than the previous agreement announced in May.
The Underground Network Sneaking Nvidia Chips Into China
A barely concealed network of buyers, sellers and couriers is bypassing the Biden administration’s restrictions aimed at denying China access to the highly coveted products, […]